Vir Biotechnology’s HDV Program: A Promising Investment Opportunity Amidst Market Underappreciation

Joseph Stringer, an analyst from Needham, maintained the Buy rating on Vir Biotechnology. The associated price target remains the same with $14.00.

Joseph Stringer has given his Buy rating due to a combination of factors that highlight the potential of Vir Biotechnology’s HDV program. The recent acquisition of Bluejay Therapeutics by Mirum Pharma underscores the significant interest in the Hepatitis Delta Virus (HDV) market, which is a positive indicator for Vir’s prospects. Stringer believes that Vir’s HDV asset, comprising elebsiran and tobevibart, demonstrates a superior profile compared to its competitors, supported by promising Phase 2 data.
Furthermore, the acquisition deal size and the expected approval of Gilead’s bulevirtide sNDA in 2026 reflect the high commercial potential in the HDV space. Stringer anticipates that Vir’s stock will benefit from these developments, as the market has yet to fully appreciate the value of Vir’s HDV program. This underappreciation presents an opportunity for investors, as the current stock price does not adequately reflect the potential risk-adjusted revenues.